SensitivityoftheFasciaetotheEndocannabinoidSystem:ProductionofHyaluronan-RichVesiclesandPotentialPeripheralEffectsofCannabinoidsinFascialTissue

Myofascial pain affects up to 85% of people at least once during their lifetime, and recent research suggests that fascia plays a more important role in pain generation than previously thought. Cannabis-based medications have shown promise in treating myofascial pain, but how cannabinoids work at the tissue level remains poorly understood. Previous research by this team demonstrated that human fascial tissue contains endocannabinoid receptors (CB1 and CB2), suggesting that fasciae could be both sources and modulators of pain. This study investigated whether activating these cannabinoid receptors could trigger changes in fascial tissue structure.

The researchers isolated fibroblast cells from fascial tissue samples taken from three patients (two men, one woman, average age 73) undergoing orthopedic surgery. They grew these cells in laboratory culture and treated them with HU-308, a synthetic compound that specifically activates CB2 cannabinoid receptors. They tested different doses (0-5 µM) and treatment durations (1-6 hours) to find the optimal conditions. The team used multiple analysis techniques including light microscopy, electron microscopy, and special staining methods to examine what happened to the cells after cannabinoid treatment.

They also used AM630, a CB2 receptor blocker, to confirm that any observed effects were specifically due to cannabinoid receptor activation.

Within just 1 hour of treatment with HU-308 at 2.5 µM concentration, fascial cells began producing visible vesicles (small bubble-like structures) in their cytoplasm. By 4 hours, these vesicles were clearly visible both inside cells and being released into the surrounding environment. Special staining revealed that these vesicles were rich in hyaluronan (HA), a key component of the extracellular matrix that helps tissues maintain flexibility and allows smooth gliding between tissue layers. Transmission electron microscopy confirmed the vesicles contained amorphous material secreted by the cells, with sizes ranging from 0.5-1 to 10 microns.

Importantly, when cells were treated with the CB2 receptor blocker AM630, vesicle production was completely prevented, confirming that this was a specific cannabinoid-mediated effect. The treatment did not damage cell viability at the effective dose.

This study provides the first direct evidence that cannabinoids can rapidly alter the structure and composition of fascial tissue through peripheral mechanisms, not just central nervous system effects. The rapid production of hyaluronan-rich vesicles suggests that cannabinoid treatment could increase tissue hydration and flexibility, potentially reducing fascial stiffness and improving tissue adaptability. Hyaluronan is crucial for allowing smooth gliding between fascial layers during movement, so increased HA production could directly address mechanical dysfunction associated with myofascial pain. This peripheral tissue remodeling effect, combined with the known anti-inflammatory properties of cannabinoids, may explain why cannabis-based treatments are effective for myofascial pain.

The findings suggest that therapeutic cannabinoids work through both central pain perception mechanisms and direct peripheral tissue effects, opening new avenues for developing targeted treatments that could modify fascial tissue properties without causing central nervous system side effects or addiction potential.